Omega3s appear to improve the FOXP3 regeneration biomarker in DMD

Supplementation with long-chain omega-3 polyunsaturated fatty acids (ω-3 LCPUFA) was tested in a double-blind, placebo-controlled study for six months in 31 boys with Duchenne muscular dystrophy (DMD):

• eighteen were treated with ω-3 LCPUFA and 13 with placeboLe placebo est un produit dont la présentation est identique à celle d’un médicament, mais qui ne contient pas de principe actif. Dans un essai clinique, un placebo est utilisé pour mesurer l’action réelle du médicament testé, en comparant les effets du médicament testé contenant le principe actif et ceux du placebo.;
• leukocyte mRNA levels of the muscle regeneration marker FOXP3 in ambulant participants were higher than in non-ambulant participants;
• it was correlated with the Vignos scale score after six months of supplementation;
• at the end of the study, the level of CD49d+ and CD8+ T cells was lower in the ω-3 LCPUFA group than in the placebo group.

The authors conclude that omega-3 supplementation, whose action on FOXP3 remains to be elucidated, may be of potential interest in DMD.

The muscle regeneration marker FOXP3 is associated with muscle injury in Duchenne muscular dystrophy. Yannin Hernández-de la Cruz S, Ordaz-Robles T, Antonio Villaldama-Soriano M et al. Brain Dev. 2024 Feb 21:S0387-7604(24)00027-5.